TrialBMC medicine2022

A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma.

Ning Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.